Rockefeller Capital Management
GRCE

Rockefeller Capital Management’s Grace Therapeutics GRCE Stock Holding History

Rockefeller Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-63
Closed – – 3030
2020
Q3 		$0 Hold
63
– – ﹤0.01% 2840
2020
Q2 		$1K Hold
63
– – ﹤0.01% 2521
2020
Q1 		$1K Buy
+63
New +$2.23K ﹤0.01% 2319

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rockefeller Capital Management's GRCE Position: Q4 2020 in Review

Rockefeller Capital Management sold out of Grace Therapeutics (GRCE) in Q4 2020, closing a stake of 63 shares.

Rockefeller Capital Management first reported a position in GRCE in Q1 2020 and held it in 3 quarters. The position peaked at $1K in Q2 2020. 28 funds tracked by Wall St. Rank hold GRCE as of Q4 2020.

  • Rockefeller Capital Management reported no remaining Grace Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Rockefeller Capital Management sold 63 Grace Therapeutics shares in Q4 2020.
  • Rockefeller Capital Management first reported a position in Grace Therapeutics in Q1 2020 and held it in 3 quarters.
  • Rockefeller Capital Management's Grace Therapeutics position peaked at $1K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2020.

Based on Rockefeller Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.